A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus

The prevalence of diabetes mellitus and CVD is alarming in the Saudi Arabian population. Diabetes mellitus and CVD are interconnected on several levels, including cellular and molecular events as well as epigenetic and genetic mechanisms. Screening for CVD is a priority for patients with diabetes and concomitant risk factors. The expert panel also recommends aggressive management of high blood pressure and dyslipidemia in addition to lifestyle changes and achieving glycemic targets for the prevention of CVD in patients with diabetes. Some glucose-lowering drug classes, namely SGLT2-inhibitors and GLP-1 receptor agonists, offer significant benefits on the level of cardiovascular risk reduction and are thus a powerful addition to the clinical management armamentarium in CVD and diabetes. Special consideration is also advised for patient populations with distinct clinical presentation and needs, such as coronary artery disease, heart failure, and chronic kidney disease, among others.

Authors

Institutions

Publication Details

Journal
Journal of the Saudi Heart Association
Published
2024-12-26
DOI
https://doi.org/10.37616/2212-5043.1407
Citations
3
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
1.07

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus

Mousa Akbar, Samih Lawand, Waleed AlHabeeb, Abdelfatah Elasfar et al.
3 citations
Journal of the Saudi Heart Association
Diabetes Treatment and Management
1.07
article

A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus

Mousa Akbar, Samih Lawand, Waleed AlHabeeb, Abdelfatah Elasfar, Taher S. Hassan, Saud Alsifri, Abdulhalim Jamal Kinsara, Ibrahim Jelaidan, Ahmed Aljizeeri, Kamal Alghalayini, Sarah M. Alyousif, Mohammed F. AlKheraiji.
article en
3 citations

Abstract

The prevalence of diabetes mellitus and CVD is alarming in the Saudi Arabian population. Diabetes mellitus and CVD are interconnected on several levels, including cellular and molecular events as well as epigenetic and genetic mechanisms. Screening for CVD is a priority for patients with diabetes and concomitant risk factors. The expert panel also recommends aggressive management of high blood pressure and dyslipidemia in addition to lifestyle changes and achieving glycemic targets for the prevention of CVD in patients with diabetes. Some glucose-lowering drug classes, namely SGLT2-inhibitors and GLP-1 receptor agonists, offer significant benefits on the level of cardiovascular risk reduction and are thus a powerful addition to the clinical management armamentarium in CVD and diabetes. Special consideration is also advised for patient populations with distinct clinical presentation and needs, such as coronary artery disease, heart failure, and chronic kidney disease, among others.

Journal of the Saudi Heart AssociationVol. 36(4)
King Abdulaziz University (SA), King Saud bin Abdulaziz University for Health Sciences (SA), King Saud University (SA), King Abdullah International Medical Research Center (SA), Bugshan Hospital (SA), Armed Forces Hospital (SA), Ministry of Health (SA), Ministry of Health (KW), Al-Sabah Hospital (KW), King Abdulaziz Hospital (SA), National Guard Health Affairs (SA), Hamad Medical Corporation (QA)
Novo Nordisk
Good health and well-being
Openalex Percentile: Top 18%
Diabetes Treatment and Management
1.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.